An object of the present invention is to provide a gel forming kit capable of regenerating hyaline cartilage, a gel that is formed by using the gel forming kit, and a method for producing a gel using the gel forming kit. The present invention provides a gel forming kit containing a crosslinking agent having at least two chains each of which includes a functional group capable of being covalently bonded to an amino group and includes a hydrophilic linking group, and a recombinant peptide; a gel formed by crosslinking of a recombinant peptide with a crosslinking agent having at least two chains each of which includes a functional group capable of being covalently bonded to an amino group and includes a hydrophilic linking group; and a method for producing the gel.

The present invention generally relates to a stem cell concentrate isolated from a mammalian vascularized adipose tissue, biopharmaceuticals containing such concentrate and use thereof in therapies for treating diseases in mammals.

The present disclosure describes methods of treating an injury in a subject using placental tissue streamers, engineered tissue placental tissue hybrids, suture placental tissue hybrids, placental tissue patch hybrids, and tissue hybrids, and the use of these compositions to repair, treat, or support an injury or degenerative process in a subject.

This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.

A synthetic composite material for tissue repair is disclosed which includes a first layer having an organic material and having side walls and external surface; and a second porous layer comprising an inorganic material and having side walls; wherein the first layer is in direct contact with the second layer and wherein the side walls of the first layer and the side walls of the second layer are coated with a third layer of the organic material.

An implant for the repair of bone and cartilage that includes a cell conductive zone that contains biopolymeric fibers and an osteoconductive zone that contains biopolymeric fibers and calcium-containing mineral particles. The biopolymeric fibers from one zone overlap with the fibers in the other zone forming a stable physical and mechanical integration of the two zones, thus conferring in vivo stability to the implant.

A method has been developed for repairing a cartilage lesion. The method includes bringing a three-dimensional porous substrate into direct contact with prepared bone. The three-dimensional porous substrate is fixedly coupled to a three-dimensional scaffold such that the substrate supports the scaffold. The three-dimensional porous substrate comprises at least three layers of woven fibers. The substrate is configured to be inserted into bone tissue including cartilage lesions such that the substrate and the scaffold replace the bone tissue including the cartilage lesions. The substrate and scaffold are further configured such that after the substrate and the scaffold have replaced the bone tissue including the cartilage lesions, the substrate and scaffold promote growth and integration of new bone tissue into the implant.

The present specification relates to a bioink composition for cartilage regeneration, a method for manufacturing a customized scaffold for cartilage regeneration using same, and a customized scaffold for cartilage regeneration using said manufacturing method, the bioink composition comprising: a first liquid comprising an adipose tissue-derived stromal vascular fraction, hyaline cartilage powder, and fibrinogen; and a second liquid comprising thrombin.

Compositions comprising a condensed mesenchymal cell body and a hydrogel are provided. The compositions may further include drugs or growth factors. The condensed mesenchymal cell body may include a connective tissue cell, or even a progenitor cell capable of producing connective tissue extracellular matrices such collagen and glycosaminoglycan. Also provided are methods of treating connective tissue defects, cartilage injury, and cartilage degradation.

Presented herein are personalized compositions comprising iPSCs and/or iPSC-derived cells (cells) and methods of producing personalized compositions suitable for various therapies, including chondrogenesis therapies, to be administered to an individual or a group of individuals. The cells and/or cell lines, and any compositions derived therefrom, are identified as compatible with a specific individual or specific group of individuals using an identification of a cell type indicative of compatibility such as an HLA match. The compatible cells are then used to derive personalized compositions, wherein the personalized compositions comprise one or more cell-secreted molecules suitable for therapy. It is found herein that a composition comprising one or more iPSC-derived MSCs, iPSC-derived chondrocytes, and iPSC-derived chondrons may provide improved treatment efficacy than would be offered by bone marrow-MSCs (BM-MSCs) or compositions comprising BM-MSCs.